Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Promising therapeutic efficacy and safety of a novel integrin α6-targeting peptide-drug conjugate in lung adenocarcinoma

5 Jul 2025

Abstract excerpt

BACKGROUND: Lung adenocarcinoma (LUAD) is the most prevalent subtype of lung cancer, with poor prognosis due to rapid tumor growth and resistance to current treatments. Thus, the identification of novel biomarkers and therapeutic strategies has become increasingly important in the management of LUAD. METHODS: A novel integrin α6-targeting peptide-drug conjugate, RWYD-MMAE, was designed to increase therapeutic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Adhesion Molecules Research
Share to Immunotherapy and Immune Responses
Share to Peptidase Inhibition and Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40616126
DOI: 10.1186/s12943-025-02395-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Promising therapeutic efficacy and safety of a novel integrin α6-targeting peptide-drug conjugate in lung adenocarcinomaPMID 40616126Read ↗

Targeting Histone Deacetylases 6 in Dual-Target Therapy of CancerSemantic proximity Read ↗

What is the impact of ITGβ8 on NSCLC: A systematic studySemantic proximity Read ↗

The microRNA Expression Signature of Lung Adenocarcinoma Harboring EGFR Mutations: Identification of Therapeutic Targets for EGFR-TKI Combination Therapy.Semantic proximity Read ↗

The immunomodulatory properties of the HDAC6 inhibitor ACY241 supports robust anti-tumor response in NSCLC when coupled with the chemotherapy drug OxaliplatinSemantic proximity Read ↗

Activation of Cytotoxic Lymphocytes Through CD6 Enhances Killing of Cancer CellsSemantic proximity Read ↗

A human monoclonal antibody 264RAD targeting αvβ6 integrin reduces tumour growth and metastasis, and modulates key biomarkers in vivoSemantic proximity Read ↗

Ibrutinib reverses IL-6-induced osimertinib resistance through inhibition of Laminin α5/FAK signaling.Semantic proximity Read ↗

Treatment of Thoracic SMARCA4-Deficient Undifferentiated Tumors: Where We Are and Where We Will Go.Semantic proximity Read ↗

Actin‐like protein 8 promotes cell proliferation, colony‐formation, proangiogenesis, migration and invasion in lung adenocarcinoma cellsSemantic proximity Read ↗

CDK4/6 inhibition with dual immunotherapy in chemorefractory SMARCA4-deficient undifferentiated tumor: a case report.Semantic proximity Read ↗

Effects of perioperative treatment of resectable adenocarcinoma of esophagogastric junction by immunotherapy (Adebrelimab) combined with chemotherapy (XELOX): protocol for a single-center, open-labeled study (AEGIS trial, neoadjuvant immunochemotherapy)Semantic proximity Read ↗

IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.